Investor Presentaiton

Investor Presentation First six months of 2018 Novo Nordisk is the market leader in the USA within the modern and new-generation insulin segment Slide 46 Modern insulin and new-generation insulin volume market shares in the USA - Novo Nordisk Sanofi Eli Lilly USA insulin market by segment Device penetration Modern Insulin penetration tMU Penetration CAGR volume¹: 2.4% 160 100% 60% CAGR value¹: 19.6% 140 50% 80% 120 Fast-acting 40% 100 60% 80 Premix 30% 40% 60 20% 40 Long-acting 20% 10% 20 0 0% 0% May 2013 May 2018 1 CAGR for 5-year period Source: IQVIA monthly MAT May, 2018 volume and value (DKK) figures changing diabetes May 2013 Source: IQVIA monthly MAT May, 2018 volume figures 40% 34% 25% May 2018 novo nordisk

View entire presentation